These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26687856)

  • 1. Advances in Peptide Receptor Radionuclide Therapy.
    Sabet A; Biersack HJ; Ezziddin S
    Semin Nucl Med; 2016 Jan; 46(1):40-6. PubMed ID: 26687856
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gastroenteropancreatic neuroendocrine tumors with peptide receptor radionuclide therapy.
    van Vliet EI; Teunissen JJ; Kam BL; de Jong M; Krenning EP; Kwekkeboom DJ
    Neuroendocrinology; 2013; 97(1):74-85. PubMed ID: 22237390
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update: improvement strategies for peptide receptor scintigraphy and radionuclide therapy.
    de Visser M; Verwijnen SM; de Jong M
    Cancer Biother Radiopharm; 2008 Apr; 23(2):137-57. PubMed ID: 18454684
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and clinical studies of peptide receptor radionuclide therapy.
    Pool SE; Krenning EP; Koning GA; van Eijck CH; Teunissen JJ; Kam B; Valkema R; Kwekkeboom DJ; de Jong M
    Semin Nucl Med; 2010 May; 40(3):209-18. PubMed ID: 20350630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peptide receptor radionuclide therapy: an overview.
    Dash A; Chakraborty S; Pillai MR; Knapp FF
    Cancer Biother Radiopharm; 2015 Mar; 30(2):47-71. PubMed ID: 25710506
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
    J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of dose with toxicity and tumour response to
    Cremonesi M; Ferrari ME; Bodei L; Chiesa C; Sarnelli A; Garibaldi C; Pacilio M; Strigari L; Summers PE; Orecchia R; Grana CM; Botta F
    Eur J Nucl Med Mol Imaging; 2018 Dec; 45(13):2426-2441. PubMed ID: 29785514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GEPNETs update: Radionuclide therapy in neuroendocrine tumors.
    van der Zwan WA; Bodei L; Mueller-Brand J; de Herder WW; Kvols LK; Kwekkeboom DJ
    Eur J Endocrinol; 2015 Jan; 172(1):R1-8. PubMed ID: 25117465
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 90Y Radioembolization after radiation exposure from peptide receptor radionuclide therapy.
    Ezziddin S; Meyer C; Kahancova S; Haslerud T; Willinek W; Wilhelm K; Biersack HJ; Ahmadzadehfar H
    J Nucl Med; 2012 Nov; 53(11):1663-9. PubMed ID: 22988059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: peptide receptor radionuclide therapy with radiolabeled somatostatin analogs.
    Kwekkeboom DJ; Krenning EP; Lebtahi R; Komminoth P; Kos-Kudła B; de Herder WW; Plöckinger U; ;
    Neuroendocrinology; 2009; 90(2):220-6. PubMed ID: 19713714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.
    Bodei L; Cremonesi M; Kidd M; Grana CM; Severi S; Modlin IM; Paganelli G
    Thorac Surg Clin; 2014 Aug; 24(3):333-49. PubMed ID: 25065935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term hematotoxicity after peptide receptor radionuclide therapy with 177Lu-octreotate.
    Sabet A; Ezziddin K; Pape UF; Ahmadzadehfar H; Mayer K; Pöppel T; Guhlke S; Biersack HJ; Ezziddin S
    J Nucl Med; 2013 Nov; 54(11):1857-61. PubMed ID: 24009272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretherapy prediction of nephrotoxicity after peptide radionuclide receptor therapy (PRRT).
    Denardo GL; Macey DJ
    Cancer Biother Radiopharm; 2010 Oct; 25(5):507-9. PubMed ID: 20849311
    [No Abstract]   [Full Text] [Related]  

  • 15. Peptide Receptor Radionuclide Therapy: Looking Back, Looking Forward.
    Feijtel D; de Jong M; Nonnekens J
    Curr Top Med Chem; 2020; 20(32):2959-2969. PubMed ID: 32101125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant peptide receptor radionuclide therapy for an inoperable neuroendocrine pancreatic tumor.
    Kaemmerer D; Prasad V; Daffner W; Hörsch D; Klöppel G; Hommann M; Baum RP
    World J Gastroenterol; 2009 Dec; 15(46):5867-70. PubMed ID: 19998512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response and long-term control of bone metastases after peptide receptor radionuclide therapy with (177)Lu-octreotate.
    Ezziddin S; Sabet A; Heinemann F; Yong-Hing CJ; Ahmadzadehfar H; Guhlke S; Höller T; Willinek W; Boy C; Biersack HJ
    J Nucl Med; 2011 Aug; 52(8):1197-203. PubMed ID: 21764798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
    Sonbol MB; Halfdanarson TR; Hilal T
    JAMA Oncol; 2020 Jul; 6(7):1086-1092. PubMed ID: 32297906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peptide-based radiopharmaceuticals for targeted tumor therapy.
    Dong C; Liu Z; Wang F
    Curr Med Chem; 2014; 21(1):139-52. PubMed ID: 23992337
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Combined Peptide Receptor Radionuclide Therapy and Liver Selective Internal Radiation Therapy in a Patient With Metastatic Neuroendocrine Tumor.
    Maccauro M; Follacchio GA; Spreafico C; Coppa J; Seregni E
    Clin Nucl Med; 2019 Apr; 44(4):e286-e288. PubMed ID: 30789395
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.